Thursday, 28 January 2021

Dennis Calvert Shared BioLargo's 2020 Accomplishments and What's to Come in a Proactive One2One Live Virtual Forum



January 26th, 2021 Recording
BioLargo Inc presents at the Proactive One2One Live Virtual Forum
BioLargo Inc (OTCMKTS:BLGO), CEO Dennis Calvert, pitches to investors at the Proactive One2One Virtual Forum. The innovative technology developer and environmental engineering company is driven by a mission to 'make life better', by delivering robust, sustainable solutions for a broad range of industries and applications. 

Tuesday, 26 January 2021

BioLargo's AEC Removal of Forever Chemicals PFAS is Confirmed 99.995% Effective in Lab Analysis Performed at the University of Tennessee

AEC Features Dramatic Reduction in Carbon Footprint Associated with Disposal

WESTMINSTER, CA / January 26, 2021 / BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and a full-service environmental engineering company, today announced new testing on its AEC water technology system, which has been proven to remove 99.9% of PFAS (so called "forever chemicals") from water in a single pass. PFAS chemicals are a new focus of the Biden Administration, who's nominee for EPA Administrator, Michael Regan, is being heralded by environmental groups for his work combatting PFAS contamination in North Carolina.

PFAS are a class of man-made chemical contaminants that are bioaccumulative and are associated with a host of serious health problems. Last week the US EPA announced it had issued "final regulatory determinations" to that will officially regulate safe levels of PFAS chemicals in drinking water.

Testing at the University of Tennessee in Knoxville showed that PFAS compounds are attracted and bound to the surface of the AEC's proprietary membranes, which in a single pass collect over 99.995%, such that less than one out of 50,000 PFAS molecules was able to penetrate the membrane.

Randall Moore, President of BioLargo Engineering commented, "This study confirms that the AEC is effective to selectively extract PFAS from water in an extraordinarily cost-effective way. Competing technologies reliant on carbon media create a significant amount of carbon waste that is often incinerated, releasing greenhouse gas emissions. This new study confirms the AEC reduces the waste produced to a fraction of the competition - imagine that to treat the same volume of water, while carbon solutions will create a truckload of spent carbon for disposal, our AEC system will create a waste product the size of a brief case."

Dennis P. Calvert, CEO at BioLargo commented, "With the recent EPA action and Biden Administration's focus on these ‘forever chemicals,' our AEC technology is in a position to become an industry standard. Thankfully, our team recognized the need for efficient removal for PFAS early and has invested the last two years developing the AEC to a now ready for commercialization stage. We are preparing for commercial trials as soon as possible and have a number of municipal water agencies that want to work with us. We expect to share more information about our AEC as it progresses."

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BLGO holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BLGO has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. Several of our technologies are commercially available and are advancing as disrupters in their respective markets. See our website at www.BioLargo.com.

Contact Information

Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863

Safe Harbor Act - caution regarding forward looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company's business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.


 

Monday, 25 January 2021

 

BioLargo Generates Record Revenue in 2020

President and CEO Dennis P. Calvert to highlight significant growth opportunities at upcoming investor conference this Tuesday, January 26th, 2021

WESTMINSTER, CA / ACCESSWIRE / January 25, 2021 / BioLargo, Inc. (OTCQB:BLGO), a developer of sustainable technologies and a full-service environmental engineering company, today announced record annual revenues in 2020 and record quarterly revenues in the fourth quarter of 2020. BioLargo President and CEO Dennis P. Calvert will be discussing how the company intends to capitalize on recent growth by executing new product launches in 2021 in his upcoming investor presentation on January 26, 2021 (details below).

In the year ended December 31, 2020, BioLargo generated approximately $2.4 million in revenue, a 31% increase compared to the previous year. In the quarter ended December 31, 2020, BioLargo generated approximately $900,000 in company-wide revenue, a 36% increase compared to the prior quarter. (These results are not yet audited.)

In addition to setting revenue records, during 2020 BioLargo also reduced its debt obligations by converting approximately $3.7 million in notes payable to equity.

BioLargo President and CEO Dennis P. Calvert commented, "2020 was a great year of important accomplishments - increased revenue, product breakthroughs and reduction of debt to manageable levels. We fully expect that revenue will continue growing, and we will continue concentrating on improving our balance sheet. Of our remaining debt, over $1 million is owed solely by Clyra Medical, over $500,000 is SBA loans, some of which will be forgiven, and $1.1 million may be converted to equity by the investors."

Dennis will be discussing the company's recent growth and its plans to accelerate its revenues with new water technology product launches in an investor presentation hosted by Proactive Investors on January 26, 2021. BioLargo's presentation is in the 10:00 AM PST / 1:00 PM EST time slot. Highlights will include the commercial pilot project where the AOS water treatment system will turn poultry processing wastewater into reusable water, the municipal wastewater treatment pilot featuring the AOS and BioLargo's new water technology, the AEC, which can effectively remove PFAS chemicals from water, and the progress on the company's operational subsidiaries efforts at profitability.

Registration for the event (free) can be done here: https://www.proactiveinvestors.com/register/event_details/316

About BioLargo, Inc.

BioLargo, Inc. (OTCQB:BLGO) invents, develops, and commercializes innovative platform technologies to solve challenging environmental problems like PFAS contamination, advanced water and wastewater treatment, industrial odor and VOC control, air quality control, and infection control. With over 13 years of extensive R&D, BLGO holds a wide array of issued patents, maintains a robust pipeline of products, and provides full-service environmental engineering. Our peer-reviewed scientific approach allows us to invent or acquire novel technologies and develop them to maturity through our operating subsidiaries. With a keen emphasis on collaborations with academic, municipal, and commercial organizations and associations, BLGO has proven itself with over 80 awarded grants and numerous pilot projects. We monetize through direct sales, recurring service contracts, licensing agreements, strategic joint venture formation and/or the sale of the IP. Several of our technologies are commercially available and are advancing as disrupters in their respective markets. See our website at www.BioLargo.com.

Contact Information
Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863

Safe Harbor Act - caution regarding forward looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company's business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

Wednesday, 20 January 2021

BioLargo: Meet the engineering company dedicated to sustainability in water, air and health

Source: Proactive investors

Join BioLargo, Phunware and Recruiter.com at the Proactive One2One Investor Forum on January 26

BioLargo Inc (OTCQB:BLGO) is an environmental engineering company with a simple mission: “To make life better” when it comes to clean water, clear air and good health.

The Westminster, California company operates four subsidiaries: Odor-No-More Inc, BioLargo Water Inc, BioLargo Engineering, Science & Technologies Inc (BLEST) and Clyra Medical Technologies Inc. 

Odor-No-More’s flagship product is CupriDyne Clean, which effectively eliminates odors rather than just masking them. BioLargo sees it as a boon for cannabis production sites, 15,000 of which can be found in California.

To deliver clean water, the company developed the Advanced Oxidation System, an industrial water treatment technology that eliminates pathogens and contaminants with greater energy efficiency and at lower cost.

Clyra Medical is developing a skin cell therapy to heal chronic wounds, but it's also managed to create a disinfectant spray that can completely deactivate the coronavirus on surfaces.

This hydra of a company is one of three high-growth potential firms presenting at the latest Proactive One2One Investor Forum on Tuesday, January 26.

CLICK HERE TO REGISTER

About the event:

  • Ours is an audience of astute high net worth investors, fund managers, private client brokers and analysts

  • We look beyond the numbers and meet the people creating the value for shareholders

The format:

  • Each company has a presentation slot followed by Q & A, giving you the chance to discover the real story
  • You can watch the event afterwards on our YouTube channel

CLICK HERE TO REGISTER

Tuesday, 19 January 2021

BioLargo Completes Manufacture of First Commercial-Scale AOS Unit for Municipal Wastewater Treatment Plant

Westminster, CA – January 19, 2021 – BioLargo, Inc. (OTCQB:BLGO), developer of cutting-edge environmental technologies and a full-service engineering company, announced today that it has completed manufacturing of its first-ever commercial-scale AOS water treatment unit, which will be shipped to a municipal wastewater treatment plant near Montréal, Québec for a pilot project. The pilot is to be run independently by water treatment technology experts from the world-renowned Centre des Technologies de l’Eau (CTE) in Montreal and will provide real-time data of AOS performance in a municipal wastewater stream. Pictures of the commercial AOS unit are provided below.

The unit being shipped can treat up to 100 gallons per minute of municipal wastewater, and will eliminate bacteria, viruses, and other organisms. As a modular design, it can easily be scaled up by adding modules to treat whatever volumes are needed to manage required wastewater streams for the customer. Unlike other wastewater disinfection systems, the AOS has been shown to remove micropollutants (including, but not limited to estradiol, benzo[a]pyrene, ibuprofen, and amoxicillin) from the wastewater. The unit comes complete with industrial controls, sensors, and is designed to operate in the field for extended periods without supervision.

A photo gallery of the commercial-scale AOS unit can be found on the company’s blog here: https://www.biolargo.com/case-studies


















The pilot project will provide crucial field validation data for the municipal wastewater market and will highlight the value proposition of the AOS – high performance, able to remove hard-to-remove micropollutants, and low operating costs, including the consumption of less electrical energy than competing technologies. Later this year, BioLargo intends to add its AEC technology, which removes per- and poly-fluoroalkyl substances (PFAS) from water more affordably while producing less waste than other technologies, to the pilot project. More information about the pilot can be found in the company’s previous press release which announced the pilot: https://biolargo.blogspot.com/2020/08/biolargo-announces-municipal-wastewater.html.

BioLargo President & CEO Dennis P. Calvert commented, “This is a critical moment for the commercialization of the AOS. We are delivering a full commercial-scale AOS unit, robust enough to handle high volumes of water over an extended period of time, and which includes all the controls required for a commercial unit. This pilot showcases the AOS and provides future customers with a success story that helps them recognize the extraordinary performance, micropollutant removal, and cost- and energy-efficiency of the AOS.”

 

About BioLargo, Inc.

BioLargo, Inc. is an innovator of technology-based products and environmental engineering solutions provider driven by a mission to “make life better”.  We feature unique disruptive solutions to deliver clean air, clean water and a clean, safe environment (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, ONM Environmental, Inc. (www.onmenvironmental.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. We are a minority stockholder of and technology licensor to our subsidiary Clyra Medical which features its breakthrough product Clyraguard (www.clyramedical.com/clyraguard), an FDA Registered, hospital grade disinfectant for personal protective equipment including facemasks, proven 99.999% effective and safe for skin, as well as its other products offering gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

During the course of the stockholder presentation, BioLargo may make “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995, regarding future events or the future financial performance of the company that are subject to change. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as “expect,” “estimate,” “project,” “budget,” “forecast,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “should,” “believes,” “predicts,” “potential,” “continue,” and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results.

Wednesday, 6 January 2021

BioLargo Discusses 2021 Goals for Growth with The Stock Day Podcast

Phoenix, Arizona--(Newsfile Corp. - January 6, 2021) - The Stock Day Podcast welcomed BioLargo, Inc. (OTCQB: BLGO), developer of cutting-edge environmental technologies and a full-service engineering company for an interview. President and CEO of BioLargo, Dennis P. Calvert, joined Stock Day host Everett Jolly.

Jolly began the interview by asking about the publication of a recent peer-reviewed paper about BioLargo's AOS water treatment system. "This is a really special asset…It represents a technical breakthrough in efficiency for high level disinfection and for extracting what the industry calls micropollutants," said Calvert, noting "that's an area of increasing concern by regulators," some of which are regulated already.

"This innovation that we have created has gone through a full development cycle. It is a state-of-the-art technical breakthrough in [water treatment] efficiency," said Calvert, before elaborating on the value of the positive confirmations shown in the peer-reviewed paper. "This is a credentialing stamp," he explained, adding that the paper has proven that the AOS is effective, efficient, and safe, and that scalable AOS models are now being manufactured. "In any given moment, about a third of the market could use this innovation in their system," Calvert says.

"We've got our first customer. It's a project [for the AOS] worth about half a million dollars in total," shared Calvert. "The future is really bright for the asset. Now we're in the process of interviewing distributors, [developing] our first customers, and we think the future of our water innovation is really pretty exciting."

Jolly commented on BioLargo's record revenues and asked about the potential of the first three quarters of 2021. Calvert started by describing the growth its air quality control division, ONM Environmental, is experiencing. "We're finding ourselves with showcase accounts that are becoming increasingly large. It's a testimony to the science, it's a testimony to the innovation of creating this [odor and VOC control product] delivery model," said Calvert, adding that the Company has built up a backlog of work in their other divisions.

"We're having organic real-time growth," shared Calvert. "We've also got our PFAS solution coming to market in 2021 for commercial trials," shared Calvert, noting the huge size and value of PFAS water treatment markets.

Calvert shared that BioLargo is on track to hit a new record for annual revenue for 2020. "The rate of growth is a record," added Calvert. "The engineers are entering into the quarter with $1.6 million in backlog," said Calvert, and "the ONM operation has approximately a quarter of a million in backlog," he continued.

"How far away are we from positive cash flow, and how are we going to maintain operations until we get to that point?" asked Jolly. Calvert explained, "We want to raise the capital only necessary to get through that gap and then expand with a proven track record for growth capital to really accelerate the growth and start driving profits and revenues for our shareholders," explained Calvert, before elaborating on the Company's robust portfolio. "What we're focused on as a company is just getting it done."

"First thing's first, let's get ourselves to break even, chart the course, and really start generating the kind of cash and profits that our shareholders want, need, and deserve, and we think that's much closer in hand than you might think," closed Calvert.

To hear the entire interview, follow the link to the podcast here: https://audioboom.com/posts/7765702-biolargo-discusses-2021-goals-for-growth-with-the-stock-day-podcast

Investors Hangout is a proud sponsor of "Stock Day," and Stock Day Media encourages listeners to visit the company's message board at https://investorshangout.com/


About BioLargo, Inc.

BioLargo, Inc. is an innovator of technology-based products and environmental engineering solutions provider driven by a mission to "make life better". We feature unique disruptive solutions to deliver clean air, clean water and a clean, safe environment (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, ONM Environmental, Inc. (www.onmenvironmental.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) developed the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. We are a minority stockholder of and technology licensor to our subsidiary Clyra Medical which features its breakthrough product Clyraguard (www.clyramedical.com/clyraguard), an FDA Registered, hospital grade disinfectant for personal protective equipment including facemasks, proven 99.999% effective and safe for skin, as well as its other products offering gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

Contact Information

Dennis P. Calvert
President and CEO, BioLargo, Inc.
888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo's (the "Company") expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company's business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company's business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company's products. More information on these risks and other potential factors that could affect the Company's business and financial results is included in the Company's filings with the SEC, including in the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of the Company's most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.

About The "Stock Day" Podcast

Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America. Stock Day recently launched its Video Interview Studio located in Phoenix, Arizona.

SOURCE:
Stock Day Media
(602) 821-1102

Monday, 4 January 2021

Peer-Reviewed Paper Confirms BioLargo’s Advanced Oxidation System Safely Removes Micropollutants from Wastewater

Westminster, CA – January 4, 2021 – BioLargo, Inc. (OTCQB:BLGO), developer of cutting-edge environmental technologies and a full-service engineering company, announced the publication of a peer-reviewed scientific paper in the Journal of Environmental Management confirming that the energy-efficient and cost-effective Advanced Oxidation System (AOS) water disinfection system also safely removes certain micropollutants from municipal wastewater. The paper concludes that the AOS is “a promising and environmentally friendly technology for wastewater treatment, remediation, and management”, highlighting the additional value the AOS can provide customers by addressing an important and poorly served technical need in the water industry. Dr. Greg Goss, in the Faculty of Science at the University of Alberta and the researcher who led the study, commented “The AOS is a major technological breakthrough for the treatment of micropollutants.”

Micropollutants are widespread synthetic chemicals that end up in municipal water supplies around the world. They originate from pharmaceuticals, personal care products, detergents, pesticides and more, and are linked to ecological damage and human health issues. They are distinct from other water contaminants because they are difficult and expensive to remove using conventional technologies such as UV, ozone, and biological treatment.

The need for cost-effective treatment of micropollutants in water and wastewater is well recognized in the water industry. One significant issue with municipal wastewater is the feminization of fish in the receiving environment due the presence of endocrine disrupting chemicals (EDC) such as estradiol. This paper reports that the BioLargo AOS effectively removes the EDC effects of estradiol commonly present in municipal wastewater. The other micropollutant tested in the study, benzo[a]pyrene, is regulated by the EPA pursuant to the Safe Water Drinking Act. The U.S. EPA maintains a published list of “contaminants of emerging concern” that includes a number of additional micropollutants in municipal wastewater that may cause ecological or human health impacts, but are not yet regulated. As regulatory scrutiny continues to increase surrounding micropollutants, municipalities are seeking technologies that can affordably and safely remove them from their wastewater streams to prevent surface water contamination.

BioLargo’s ground-breaking and patented Advanced Oxidation System (AOS) is a water treatment platform that provides high-level disinfection and consumes less electricity than competing technologies. The AOS’ ability to eliminate the deleterious effects of micropollutants in wastewater offers significant additional value to the municipal wastewater treatment market by providing affordable and effective micropollutant removal in addition to its primary use as an energy-efficient and cost-effective wastewater disinfection technology.

 

Two significant commercial-scale AOS projects are starting in the coming year. The first, at a municipal wastewater treatment plant near Montreal, Canada, will assess the AOS’ ability to efficiently disinfect and remove micropollutants and other organic contaminants at an operating municipal wastewater treatment plant. The second will treat poultry-processing wastewater at a certified organic farm in Alberta, Canada. The development of the AOS, and both pilot projects, are being led by BioLargo’s Alberta, Canada, based subsidiary, BioLargo Water. In addition to these two commercial-scale pilot projects, BioLargo is now screening potential distributors in North America.

Dr. Richard Smith, President of BioLargo Water, commented, “We will be shipping our first commercial-scale AOS unit in the coming weeks to the wastewater treatment plant near Montreal, and will install our first full-scale ‘zero liquid discharge’ system in our project with Sunworks Farms in Alberta in the first half of 2021. These initial projects will help demonstrate the substantial value the AOS provides in wastewater treatment, and we believe will ultimately lead to significant market adoption.”

To read the peer-reviewed published paper, visit: https://authors.elsevier.com/a/1cHo114Z6telDf

Highlights from
the paper:

  • AOS is highly effective at eliminating the negative effects of two particularly difficult micropollutants, suggesting it may be effective against a wide range of similar compounds.
  • The AOS requires extremely low levels of electric energy to operate.
  • The AOS did not increase toxicity or introduce additional hazards (i.e., decontamination by-products) in the post-treatment effluent.

This work was funded in part by the Canadian Natural Science and Engineering Research Council (NSERC) and the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP).

To learn more about BioLargo Water and the AOS, visit www.biolargowater.com and the website of its parent company BioLargo at www.biolargo.com.

 

About BioLargo, Inc.

BioLargo, Inc. is an innovator of technology-based products and environmental engineering solutions provider driven by a mission to “make life better”.  We feature unique disruptive solutions to deliver clean air, clean water and a clean, safe environment (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, ONM Environmental, Inc. (www.onmenvironmental.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) developed the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. We are a minority stockholder of and technology licensor to our subsidiary Clyra Medical which features its breakthrough product Clyraguard ( www.clyramedical.com/clyraguard), an FDA Registered, hospital grade disinfectant for personal protective equipment including facemasks, proven 99.999% effective and safe for skin, as well as its other products offering gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.

Contact Information

Dennis P. Calvert

President and CEO, BioLargo, Inc.

888-400-2863

Safe Harbor Act

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include without limitation those about BioLargo’s (the “Company”) expectations regarding the impact of the COVID-19 pandemic; anticipated revenue; and plans for future operations. These statements involve risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the COVID-19 pandemic on the Company’s business, results of operations, financial condition, and stock price; the effect of regional economic conditions on the Company’s business, including effects on purchasing decisions by consumers and businesses; the ability of the Company to compete in markets that are highly competitive and subject to rapid technological change; the ability of the Company to manage frequent introductions and transitions of products and services, including delivering to the marketplace, and stimulating customer demand for, new products, services, and technological innovations on a timely basis; the dependency of the Company on the performance of distributors of the Company’s products. More information on these risks and other potential factors that could affect the Company’s business and financial results is included in the Company’s filings with the SEC, including in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s most recently filed periodic reports on Form 10-K and Form 10-Q and subsequent filings. The Company assumes no obligation to update any forward-looking statements or information, which speak as of their respective dates.